Visit COVID-19 resources

[Skip to Content]

Age-related macular degeneration

New Guidance for Commissioning Age Related Macular Degeneration Services

The Royal College of Ophthalmologists (RCOphth) has developed Age Related Macular Degeneration Commissioning Guidance June 2021. The National Institute for Health and Care Excellence (NICE) has  accredited the process used by The Royal College of Ophthalmologists to develop this guidance. It sets out the  principles and minimum standards of care for AMD to decrease variations

National Ophthalmology Database Funding boost for new UK AMD Audit

The Royal College of Ophthalmologists (RCOphth) is delighted to announce that the National Ophthalmology Database (NOD) Audit: Age-Related Macular Degeneration has now received funding for three years, enabling this important programme of long-term research and data gathering to begin. Age-related macular degeneration (AMD) remains a leading cause of sight impairment despite new treatment options. It

Clinical Guidelines

Our guidelines are systematically generated to help clinicians make better decisions about appropriate healthcare for specific eye disorders, enhancing clinician and patient decision making by describing and appraising the scientific evidence and reasoning behind clinical recommendations. They are developed to make recommendations for the majority of clinical situations; however they are intended as an aid

Age-related Macular Degeneration

Age-related Macular Degeneration (AMD) is a long term condition which is the leading cause of sight loss in the UK. Sight loss often occurs quickly with the exudative (“wet”) form of AMD but can be stabilised or improved in most cases with prompt treatment and timely monitoring. The main objective for an AMD service is